Recently, we have shown that Hecate-CGβ conjugate, which is a fusion of the lytic peptide Hecate and a 15–amino acid fragment of the β-chain of chorionic gonadotropin (CGβ), selectively destroys mammary gland carcinoma cells that possess luteinizing hormone receptors (LHR) in vitro. We induced mammary gland tumors using combined prenatal exposure to synthetic diethylstilbestrol (DES) and additional postnatal exposure to dimethylbenz[a]anthracene (DMBA). Rats with tumors were equally randomized (10/group) and treated with either sham (control) or 12 mg/kg body wt of either Hecate or Hecate-CGβ once a week for 3 weeks by tail vein injections. One week after the last injection, rats were kilted. Reverse-transcription–nested polymerase chain reaction/Southern blotting revealed alternatively spliced mRNA for LHR in tumor tissues of 5 of 30 females, which was further confirmed by Western blot analysis. The percentage of tumor volume increase was lowest in the group treated with Hecate-CGβ (45.3 ± 27.6), compared with Hecate- and shamtreated, control group (324.8 ± 78.1 and 309.9 ± 51.2, respectively; P < 0.001). Hecate-CGβ induced a significant decrease in tumor burden compared with controls (9.5 ± 2.1 mg/g body wt vs. 21.6 ± 2.9; P < 0.01). A smaller reduction in tumor burden was also observed in Hecate-treated females (17.6 ± 1.6 mg/g body wt vs. 21.6 ± 2.9; P < 0.05). Our results prove the principle that Hecate-CGβ conjugate is able to repress mammary gland tumor growth, even in tumor tissues that lack or have very low levels of LHR. The mechanism of Hecate-CGβ conjugate action in repression of DES/DMBA-induced tumor growth needs to be further analyzed to clarify the molecular mechanisms of Hecate-CGβ conjugate action in vivo.
GreenleeR, Hill-HarmaM, MurrayT, ThunM.Cancer statistic 2001. Cancer J Clin51:15–36, 2001.
2.
KellandLR. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin Invest Drugs12:413–421, 2003.
3.
MagrathIT. Targeted approaches to cancer therapy. Int J Cancer56:163–166, 1994.
4.
GiustiRM, IwamotoK, HatchEE. Diethylstilbestrol revised: a review of the long-term health effect. Ann Intern Med122:778–788, 1995.
5.
McLachlanJA, NewboldRR, BullockB.Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science190:991–992, 1975.
6.
GillWB, SchumacherGF, BibboM.Structural and functional abnormalities in the sex organs of male offspring of mothers treated with diethyldtilbestrol (DES). J Reprod Med16:147–153, 1976.
7.
BibboM, GillWB, AziziF, BloughR, FangVS, RosenfieldRL, SchumacherGF, SleeperK, SonekMG, WiedGL. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol49:1–18, 1977.
8.
NomuraT, KanazakiT.Induction of urogenital anomalies and some tumors in the progeny of mice receiving diethylstilbestrol during pregnancy. Cancer Res37:1099–1104, 1977.
9.
BoylanES. Morphological and functional consequences of prenatal exposure to diethylstilbestrol in the rat. Biol Reprod19:854–863, 1978.
10.
NewboldRR, HansonRB, JeffersonWN, BullockBC, HasemanJ.McLachlanJA. Increased tumors but uncompromised fertility in the female descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis19:1655–1663, 1998.
11.
WalkerBE, KurthLA. Multi-generational carcinogenesis from diethylstilbestrol investigated by blastocyst transfer in mice. Int J Cancer61:249–252, 1995.
12.
RussoIH, KoszalkaM, GimottyPA, RussoJ.Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis. Br J Cancer62:243–247, 1990.
13.
RussoIH, KoszalkaM, RussoJ.Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst. 82:1286–1289, 1990.
14.
RussoIH, KoszalkaM, RussoJ.Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Br J Cancer64:481–484, 1991.
15.
IlesR.β hCG expression by bladder cancers. Br. J. Cancer65: 305, 1992.
16.
MoutzourisG, YannopoulosD, BarbatisC, ZaharofA, TheodorouC.Is β-human chorionic goonadotropin production by transitional cell carcinoma of the blabber a marker for aggressive disease and resistance to radiotherapy? Br J Urol72:907–909, 1993.
17.
AcevedoHF, TongJY, HartsockRJ. Human chorionic gonadotropin β subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer76:1467–1475, 1995.
18.
AcevedoHF, KirchevskyA, Campbell-AcevedoEA, GaylonJC, BuffoMJ, HartsockRJ. Expression of membrane associated human chorionic gonadotropin, its subunit, and fragments by cultured human cancer cells. Cancer69:1829–1842, 1992.
19.
MeduriG, ChamauxN, LoosfeltH, JolivetA, SpyratosF, BraillyS, MilgromE.Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res57:857–864, 1997.
20.
TaoXY, LeiZM, RaoCV. The presence of luteinizing hormone/human chorionic gonadotropin receptors in lactating rat mammary glands. Life Sci60:1297–1303, 1997.
21.
LojunS, BaoS, LeiZM, RaoCV. Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against cancer. Biol Reprod57:1202–1210, 1997.
22.
KelseyJL, GammonMD, JihnEM. Reproductive factors and breast cancers. Epidemiol Rev15:36–47, 1993.
23.
RaoCV. Does full-term pregnancy at a young age protect women against breast cancer through hCG? Obstet Gynecol96:783–786, 2000.
24.
AlvaradoMV, AlvardoNE, RussoJ, RussoIH. Human chorionic gonadotropin inhibits proliferation and induces expression of inhibin in human breast epithelial cells in vitro. In vitro Cell Dev Biol Anim30A:4–8, 1994.
25.
AlvaradoMV, RussoJ, RussoIH. Immunolocalization of inhibin in the mammary gland of rats treated with hCG. J Histochem Cytochem41:29–34, 1993.
26.
AlvaradoMV, HoTY, RussoJ, RussoIH. Human chorionic gonadotropin regulates the synthesis of inhibin in the ovary and mammary gland of rat. Endocrine2:1107–1114, 1994.
27.
SchallyAV, NagyA.Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol141:1–14, 1999.
28.
LeuschnerC, EnrightFM, MelroseA, HanselW.Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptor. Prostate46:116–125, 2001.
29.
HanselW, LeuschnerC, GawronskaB, EnrightF.Targeted destruction of prostate cancer cells and xenografts by lytic peptide-βLH conjugates. Reprod Biol1:20–32, 2001.
30.
GawronskaB, LeuschnerC, EnrightFM, HanselW.Effects of lytic peptide conjugated to β hCG on ovarian cancer: studies in vivo and in vitro. Gynecol Oncol85:45–52, 2002.
31.
LeuschnerC, EnrightFM, GawronskaB, HanselW.Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat78:17–27, 2003.
32.
BodekG, RahmanNA, ZaleskaM, SoliymaniR, LankinenH, HanselW, HuhtaniemiI, ZiecikAJ. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGβ conjugate. Breast Cancer Res Treat79:1–10, 2003.
33.
ZaleskaM, BodekG, JanaB, HanselW, ZiecikAJ. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-βCG conjugate. Exp Clin Endocrinol Diabetes111:146–153, 2003.
34.
BoylanES, CalhoonRE. Transplacental action of diethylstilbestrol on mammary carcinogenesis in female rats given one or two doses of 7,12-dimethylbenz(a)anthracene. Cancer Res43:4879–4884, 1983.
35.
TomaykoMM, ReynoldsCP. Determination of subcutaneous tumor size in anthymic (nude) mice. Cancer Chemother Pharmacol24:148–154, 1989.
36.
SzafranskaB, TiltonJE. Prolactin as a luteotrophin during late pregnancy in pigs. J Reprod Fertil98:643–648, 1993.
37.
HaavistoAM, PetterssonK, BergendahlM, PerheentupaA, RoserJF, HuhtaniemiI.A supersensitive immunofluorometric assay for rat luteinizing hormone. Endocrinology132:1687–1691, 1993.
38.
Van CasterenJI, SchoonenWG, KloosterboerHJ. Development of time-resolved immunofluorometric assays for rat follicle-stimulating hormone and luteinizing hormone and application on sera of cycling rats. Biol Reprod62:886–894, 2000.
39.
BergendahlM, PerheentupaA, HuhtaniemiI.Effect of short-term starvation on reproductive hormone gene expression, secretion and receptor levels in male rats. J Endocrinol121:409–417, 1989.
40.
SambrookJ, FritschEF, ManiatisT.Molecular Cloning: A laboratory manual. New York:Cold Spring Harbor Laboratory Press, 1989.
41.
StepienA, ShemeshM, ZiecikAJ. Luteinizing hormone receptor kinetic and LH-induced prostaglandin production throughout the oestrus cycle in porcine endometrium. Reprod Nutr Dev39:663–674, 1999.
42.
BradfordMM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem72:248–254, 1976.
43.
BaoR, SelvakumaranM, HamiltonTC. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol Oncol78:373–379, 2000.
44.
JohnstoneSA, GelmonK, MayerLD, HancockRE, BallyMB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Res 15:151–160, 2000.
45.
BoylanES, CalhoonRE, VonderhaarBK. Transplacental action of diethylstilbestrol on reproductive end endocrine organs, mammary glands, and serum hormone levels in two- or nine-month-old female rats. Cancer Res43:4872–4878, 1983.
46.
LoosfeltH, MisrahiM, AtgerM, SalesseR, Vu Hai-Luu ThiMT, JolivetA, Guiochon-MantelA, SarS, JallalB, GamierJ, MilgromE.Cloning and sequencing of porcine LH-hCG receptor cDNA: variants lacking transmembrane domain. Science245:525–528, 1989.
47.
KooYB, JiI, SlaughterRG, JiTH. Structure of the luteinizing hormone receptor gene and multiple exons of the coding sequence. Endocrinology128:2297–2308, 1991.
48.
Tsai-MorrisCH, BuczkoE, WangW, XieX-Z, DufauML. Structural organization of the luteinizing hormone (LH) receptor gene. J Biol Chem266:113355–11359, 1991.
49.
BernardMP, MyersRV, MoyleWR. Cloning of rat lutropin (LH) receptor analogs lacking the soybean lectin domain. Mol Cell Endocrinol71:R19–23, 1990.
50.
SegaloffDL, SprengelR, NikolicsK, AscoliM.Structure of the lutropin/choriogonadotropin receptor. Recent Prog Horm Res46:261–301, 1990.
51.
Tsai-MorrisCH, BuczkoE, WangW, DufauML. Intronic nature of the rat luteinizing hormone receptor gene defines a soluble receptor subspecies with hormone binding activity. J Biol Chem265:19385–19388, 1990.
52.
AatsinkiJT, PietilaEM, LakkakorpiJT, RajaniemiHJ. Expression of the LH/CG receptor gene in rat ovarian tissue is regulated by an extensive alternative splicing of the primary transcript. Mol Cell Endocrinol84:127–135, 1992.
SokkaT, HamalainenT, HuhtaniemiL.Functional LH receptor appears in the neonatal rat ovary after changes in the alternative splicing pattern of the LH receptor mRNA. Endocrinology130:1738–1740, 1992.
55.
ZhangFP, HamalainenT, KaipiaA, PakarinenP, HuhtaniemiI.Ontogeny of luteinizing hormone receptor gene expression in the rat testis. Endocrinology134:2206–2213, 1994.
56.
RaoCV. No mRNAs for the LH/hCG receptor in human endometrium? Fertil Steril71:374–375, 1999.
57.
LoebKR, LoebLA. Significance of multiple mutations in cancer. Carcinogenesis21:379–385, 2000.
58.
ReinholzMM, ZschunkeMA, RochePC. Loss of alternately spliced messenger RNA of the luteinizing hormone receptor and stability of the follicle-stimulating hormone receptor messenger RNA in granulosa cell tumors of the human ovary. Gynecol Oncol79:264–271, 2000.
59.
SmithCW, PattonJG, Nadal-GinardB.Alternative splicing in the control of gene expression. Annu Rev Genet23:527–577, 1989.
60.
LeiZM, RaoCV, KornyeiJL, LichtP, HiattES. Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. Endocrinology132:2262–2270, 1993.
61.
PetajaU, KellokumpuS, KeinanenK, MetsikkoK, RajaniemiH.Covalent cross-linking of radiolabeled human chorionic gonadotropin to rat ovarian luteinizing hormone receptor with glutaraldehyde. J Receptor Res7:809–827, 1987.
62.
ChanSC, YauWL, WangW, SmithDK, SheuFS, ChenHM. Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. J Peptide Sci4:413–425, 1998.
63.
PapoN, ShaharM, EisenbachL, ShaiY.A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture an in mice. J Biol Chem278:21018–21023, 2003.
